

Andrea Pilotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8152833/publications.pdf>

Version: 2024-02-01

129
papers

4,485
citations

126708

33
h-index

138251

58
g-index

150
all docs

150
docs citations

150
times ranked

7136
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. <i>Neuron</i> , 2016, 91, 56-66.	3.8	289
2	Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 192.e1-192.e11.	1.2	277
3	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020, 88, 423-427.	2.8	230
4	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
5	Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. <i>Neurology</i> , 2020, 95, e910-e920.	1.5	194
6	Long-term unsupervised mobility assessment in movement disorders. <i>Lancet Neurology</i> , The, 2020, 19, 462-470.	4.9	181
7	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021, 73, e3019-e3026.	2.9	131
8	Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease. <i>Neurology</i> , 2009, 73, 761-767.	1.5	102
9	Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 28-37.	1.9	87
10	Long-term neurological manifestations of COVID-19: prevalence and predictive factors. <i>Neurological Sciences</i> , 2021, 42, 4903-4907.	0.9	84
11	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017, 32, 1025-1034.	2.2	75
12	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α -synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	0.9	73
13	Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 20.	3.0	67
14	Altered brain metabolic connectivity at multiscale level in early Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 4256.	1.6	64
15	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 225-230.	0.7	62
16	Validation of α -Synuclein in L1CAM-Immuncaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes. <i>Movement Disorders</i> , 2021, 36, 2663-2669.	2.2	62
17	<p>Central Serous Chorioretinopathy: Pathogenesis and Management</p>. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 2341-2352.	0.9	57
18	Pharmacogenetics of cytochrome P450 (CYP) in the elderly. <i>Ageing Research Reviews</i> , 2010, 9, 457-474.	5.0	53

#	ARTICLE	IF	CITATIONS
19	Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. <i>Neurology</i> , 2018, 90, e1029-e1037.	1.5	51
20	Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. <i>Frontiers in Neurology</i> , 2021, 12, 644317.	1.1	51
21	Vascular Risk Factors and Cognition in Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 563-570.	1.2	49
22	MicroRNA-34a expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study. <i>International Journal of Molecular Medicine</i> , 2020, 47, 533-546.	1.8	49
23	Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2014, 28, 1155-1184.	2.7	48
24	Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. <i>Neurobiology of Stress</i> , 2021, 14, 100326.	1.9	48
25	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	2.8	47
26	A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack. <i>Journal of Neurology</i> , 2012, 259, 670-678.	1.8	46
27	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	0.8	45
28	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	1.7	45
29	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
30	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 563-584.	3.3	41
31	Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 398-406.	1.7	38
32	Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1642-1651.	3.3	38
33	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
34	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1416-1424.	1.3	35
35	Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging correlates. <i>Neurobiology of Aging</i> , 2015, 36, 3108-3115.	1.5	32
36	Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy. <i>Neurodegenerative Diseases</i> , 2017, 17, 286-291.	0.8	30

#	ARTICLE	IF	CITATIONS
37	Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome?. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 62-66.	1.1	29
38	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , 2021, 96, e399-e411.	1.5	29
39	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 187.	3.0	29
40	Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. <i>Neurological Sciences</i> , 2014, 35, 1215-1219.	0.9	28
41	COVID-19 impact on consecutive neurological patients admitted to the emergency department. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 218-220.	0.9	28
42	Clinical, Biological, and Imaging Features of Monogenic Alzheimer's Disease. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	27
43	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
44	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	1.8	26
45	Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review. <i>Journal of Neurology</i> , 2021, 268, 3947-3960.	1.8	26
46	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47.	1.1	26
47	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	1.8	25
48	Dementia with lewy bodies: <i>GBA1</i> mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , 2019, 34, 1069-1073.	2.2	24
49	Developments in the Role of Transcranial Sonography for the Differential Diagnosis of Parkinsonism. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 43.	2.0	23
50	Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 907-912.	1.2	23
51	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2387-2395.	3.3	23
52	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. <i>Brain Stimulation</i> , 2019, 12, 1290-1297.	0.7	23
53	Reply to the Letter "COVID-19 Associated Encephalopathy and Cytokine-Mediated Neuroinflammation". <i>Annals of Neurology</i> , 2020, 88, 861-862.	2.8	23
54	Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. <i>Annals of Neurology</i> , 2021, 89, 91-98.	2.8	23

#	ARTICLE	IF	CITATIONS
55	Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. <i>Journal of Infection</i> , 2021, 82, e4-e7.	1.7	23
56	The combined effect of amyloid- β^2 and tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 27, 102333.	1.4	22
57	Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263595.	1.1	22
58	Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2778-2780.	1.3	21
59	TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 731-740.	1.2	20
60	Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. <i>Neurological Sciences</i> , 2012, 33, 375-378.	0.9	20
61	Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential. <i>Neurotherapeutics</i> , 2020, 17, 1736-1746.	2.1	20
62	Premorbid vulnerability and disease severity impact on Long-COVID cognitive impairment. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 257-260.	1.4	20
63	Molecular signature of disease onset in Granulin mutation carriers: a gene expression analysis study. <i>Neurobiology of Aging</i> , 2013, 34, 1837-1845.	1.5	19
64	Overlap between Frontotemporal Dementia and Alzheimer's Disease: Cerebrospinal Fluid Pattern and Neuroimaging Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 49-55.	1.2	19
65	Exploring Olfactory Function and Its Relation with Behavioral and Cognitive Impairment in Amyotrophic Lateral Sclerosis Patients: A Cross-Sectional Study. <i>Neurodegenerative Diseases</i> , 2016, 16, 411-416.	0.8	19
66	Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 772-778.	1.3	19
67	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , 2017, 32, 1780-1783.	2.2	19
68	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment – the ComOn-study. <i>BMC Geriatrics</i> , 2020, 20, 45.	1.1	19
69	The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study. <i>Archives of Gerontology and Geriatrics</i> , 2021, 95, 104415.	1.4	19
70	Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. <i>Journal of Psychopharmacology</i> , 2015, 29, 623-633.	2.0	18
71	Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 162-168.	1.2	18
72	Autonomic dysfunction in subjects at high risk for Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 2643-2652.	1.8	17

#	ARTICLE	IF	CITATIONS
73	FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 941-950.	1.2	16
74	Impaired metabolic brain networks associated with neurotransmission systems in the α -synuclein spectrum. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 113-122.	1.1	16
75	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. <i>Psychological Medicine</i> , 2016, 46, 2275-2286.	2.7	14
76	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 42.	3.0	14
77	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.5	14
78	Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study. <i>Neurobiology of Aging</i> , 2020, 93, 55-60.	1.5	14
79	Functional genetic variation in the serotonin 5-HTTLPR modulates brain damage in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2015, 36, 446-451.	1.5	13
80	Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4242.	1.2	13
81	Third ventricular width assessed by transcranial ultrasound correlates with cognitive performance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 68-73.	1.1	12
82	Global survey on disruption and mitigation of neurological services during COVID-19: the perspective of global international neurological patients and scientific associations. <i>Journal of Neurology</i> , 2022, 269, 26-38.	1.8	12
83	The Italian tremor Network (TITAN): rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2022, 43, 5369-5376.	0.9	12
84	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. <i>Neurological Sciences</i> , 2017, 38, 83-91.	0.9	11
85	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. <i>Ultraschall in Der Medizin</i> , 2017, 38, 294-300.	0.8	11
86	Metal Exposure and SNCA rs356219 Polymorphism Associated With Parkinson Disease and Parkinsonism. <i>Frontiers in Neurology</i> , 2020, 11, 556337.	1.1	11
87	Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 61.	1.2	11
88	Effects of COVID-19 outbreak on stroke admissions in Brescia, Lombardy, Italy. <i>European Journal of Neurology</i> , 2021, 28, e4-e5.	1.7	11
89	Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study Using Mobile Health Technology. <i>Cerebellum</i> , 2021, 20, 662-666.	1.4	11
90	Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes. <i>Neurobiology of Disease</i> , 2022, 167, 105668.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Association between cognitive impairment and urinary dysfunction in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 543-550.	1.4	10
92	Real-world eligibility for aducanumab depends on clinical setting and patients' journey. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 626-628.	1.3	10
93	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 14.	3.0	10
94	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 991-997.	1.2	10
95	Microarray Gene and miRNA Expression Studies: Looking for New Therapeutic Targets for Frontotemporal Lobar Degeneration. <i>Drug Development Research</i> , 2014, 75, 366-371.	1.4	9
96	Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. <i>Neurobiology of Aging</i> , 2014, 35, 1206-1211.	1.5	9
97	GBA-associated parkinsonism and dementia: beyond L-synucleinopathies?. <i>European Journal of Neurology</i> , 2016, 23, 520-526.	1.7	9
98	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. <i>Neurology</i> , 2021, 96, e904-e915.	1.5	9
99	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 L-synuclein antibody. <i>Acta Neuropathologica</i> , 2014, 128, 893-5.	3.9	8
100	The effect of age and gender on anti-saccade performance: Results from a large cohort of healthy aging individuals. <i>European Journal of Neuroscience</i> , 2020, 52, 4165-4184.	1.2	8
101	Impact of SARS-CoV-2 on reperfusion therapies for acute ischemic stroke in Lombardy, Italy: the STROKOVID network. <i>Journal of Neurology</i> , 2021, 268, 3561-3568.	1.8	7
102	Voluptuary Habits and Risk of Frontotemporal Dementia: A Case Control Retrospective Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 335-340.	1.2	6
103	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 455-462.	1.5	6
104	Looking at the burden of neurological disorders in Europe. <i>Lancet Public Health</i> , The, 2020, 5, e523.	4.7	6
105	Digital assessment at home – mPower against Parkinson disease. <i>Nature Reviews Neurology</i> , 2021, 17, 661-662.	4.9	6
106	Premorbid frailty predicts short- and long-term outcomes of reperfusion treatment in acute stroke. <i>Journal of Neurology</i> , 2022, 269, 3338-3342.	1.8	6
107	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. <i>Translational Neurodegeneration</i> , 2022, 11, 24.	3.6	6
108	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	0.9	5

#	ARTICLE	IF	CITATIONS
109	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq1 1 0.784314 rgBT ₅ /Overlo	0.9	5
110	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€™DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.4	5
111	SARS-CoV-2 infection and acute ischemic stroke in Lombardy, Italy. Journal of Neurology, 2022, 269, 1-11.	1.8	5
112	Neurophysiological Correlates of Motor and Cognitive Dysfunction in Prodromal and Overt Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2022, 86, 579-588.	1.2	5
113	Gender-Related Vulnerability of Dopaminergic Neural Networks in Parkinson's Disease. Brain Connectivity, 2021, 11, 3-11.	0.8	4
114	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	1.1	4
115	Imaging features and ultraearly hematoma growth in intracerebral hemorrhage associated with COVID-19. Neuroradiology, 2022, , 1.	1.1	4
116	Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease. Mini-Reviews in Medicinal Chemistry, 2011, 11, 988-1001.	1.1	3
117	Prognostic Indicators and Outcomes of Hospitalised COVID-19 Patients with Neurological Disease: A Systematic Review and Individual Patient Data Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	3
118	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , .	0.4	3
119	Clinical outcome of neurological patients with COVID-19: the impact of healthcare organization improvement between waves. Neurological Sciences, 2022, 43, 2923-2927.	0.9	3
120	Imaging dopamine system transporter activity and connectivity in Alzheimerâ€™s dementia. Alzheimer's and Dementia, 2020, 16, e043304.	0.4	1
121	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
122	Aberrant origin of the occipital artery from the internal carotid artery: utility of the occipital tap maneuver. Journal of Vascular Surgery Cases and Innovative Techniques, 2021, 7, 743-745.	0.3	1
123	Design and Test of an Autonomous Reconfigurable Dynamic Investigation Test-Rig on Haptics (ARDITA) for Pre-Screening of the Peripheral Neuropathy Diseases. , 2018, , .		1
124	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). Neurological Sciences, 2022, 43, 4221-4229.	0.9	1
125	Extrastriatal dopaminergic and serotonergic pathways in Alzheimerâ€™s disease: A 123 Iâ€™FPâ€™CIT study. Alzheimer's and Dementia, 2020, 16, e041317.	0.4	0
126	Serum NFL as a predictor of disease progression in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041594.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Reply to Abboud. Journal of Infectious Diseases, 2021, 223, 1304-1305.	1.9	0
128	Sexual divergencies in monoaminergic projections in Parkinson's disease: A 123I-FP-CIT SPECT study. Journal of the Neurological Sciences, 2021, 429, 119484.	0.3	0
129	Neurological involvement associated with COVID-19 disease: a study on psychosocial factors. Neurological Sciences, 2022, 43, 2187-2193.	0.9	0